Microfluidic radiopharmaceutical production system and process for synthesizing per run approximately, but not less than, ten (10) unit doses of radiopharmaceutical biomarker for use in positron emission tomography (PET). A radioisotope from an accelerator or other radioisotope generator is introduced into a reaction vessel, along with organic and aqueous reagents, and the mixture heated to synthesize a solution of a pre-selected radiopharmaceutical. The solution is purified by passing through a combination of solid phase extraction purification components, trap and release components, and a filter. The synthesis process reduces waste and allows for production of biomarker radiopharmaceuticals on site and close to the location where the unit dose will be administered to the patient. On-site, as-needed production of radiopharmaceuticals in small doses reduces the time between synthesis of the radiopharmaceutical and administration of that radiopharmaceutical, minimizing loss of active isotopes through decay and allowing production of lesser amounts of radioisotopes overall.

An object is to more accurately compare diagnosis indexes with each other, which are calculated from data obtained in different environments with a cardiac-function diagnostic medicine. A conversion function calculation unit acquires a first phantom Heart/Mediastinum ratio (H/M ratio) and a second phantom H/M ratio based on a phantom, the first phantom H/M ratio that is an H/M ratio of the phantom in the first imaging environment being acquired by performing, based on phantom data that is data of a first phantom image obtained by imaging the phantom in the first imaging environment and digital phantom data that is data of a digital phantom including a cardiac ROI and a mediastinum ROI, positioning of the digital phantom on the first phantom image, and by calculating based on the phantom data of the first phantom image to which the cardiac ROI and the mediastinum ROI are set; and obtains a conversion function based on the first phantom H/M ratio and the second phantom H/M ratio.

A redox-based strategy for bioconjugation of tryptophan uses oxaziridine reagents that mimic oxidative cyclization reactions in indole-based alkaloid biosynthetic pathways to achieve highly selective and rapid tryptophan labeling.

Embodiments of the present invention generally relate to conjugates of heptamethine carbocyanine dye (HMCD)-chelator radiometal complexes, radiopharmaceutical formulations comprising such complexes and their use, in particular for internal radiotherapy and/or imaging of cancer. In particular, in embodiments, provided are DZ-1-Lys-DOTA conjugates complexed with Lutetium-177, Yttrium-90 or Gallium-68, or combinations thereof. Some embodiments provide improved radiotherapy with complexes of Lutetium-177 or Yttrium-90. Further embodiments provide improved radioimaging with Gallium-68 complexes, and their use. Yet further embodiments provide improved image-guided therapy by using matched theranostic pairs of such conjugates, wherein for therapy purposes the radiometal is selected from one or more of Lutetium-177, Yttrium-90, each of which for imaging purposes may be paired with Gallium-68, for improved image-guided radiotherapy.

Methods, reporter gene constructs, and kits for using prostate-specific membrane antigen (PSMA) as an imaging reporter to image a variety of cells and tissues are provided.

Described herein is a composition including a compound according to Formula I: wherein M is a Group 7 transition metal. R1 is selected from the group consisting of methyl, ethyl, propyl, butyl, and phenethyl; R2 is selected from the group consisting of H and methyl; R3 is selected from the group consisting of H, methyl, ethyl, propyl, butyl, and phenethyl; and R4 is selected from the group consisting of H, methyl, and -L-Z, wherein L is a linker and Z is a targeting unit. Also disclosed are methods including administering, to a patient suffering from a cancer or suspected of suffering from a cancer, the composition. Further disclosed are kits comprising the composition and instructions to perform the method.

##STR00001##

It is intended to provide a novel amino acid organic compound which can be used as a labeling precursor compound for radioactive halogen-labeled amino acid compounds including [.sup.18F]FACBC, and which prevents methanol from remaining in the radioactive halogen-labeled amino acid compounds produced therefrom. The novel amino acid organic compound is a compound represented by the following formula:

##STR00001##

wherein n is an integer of 0 or of 1 to 4; R.sup.1 is an ethyl, 1-propyl or isopropyl substituent; X is a halogen substituent or a group represented by OR.sup.2; R.sup.2 is a straight-chain or branched-chain haloalkylsulfonic acid substituent with one to 10 carbon atoms, trialkylstannyl substituent with 3 to 12 carbon atoms, fluorosulfonic acid substituent or aromatic sulfonic acid substituent; and R.sup.3 is a protective group.

The prostate-specific membrane antigen (PSMA) is increasingly recognized as a viable target for imaging and therapy of cancer. Various 99mTc/Re-labeled compounds were prepared by attaching known Tc/Re chelating agents to an amino-functionalized PSMA inhibitor with or without a variable length linker moiety. Ex vivo biodistribution and in vivo imaging demonstrated the degree of specific binding to engineered PSMA+ PC3 PIP tumors.

The present invention provides a method for the production of [.sup.18F]-FACBC which has advantages over know such methods. Also provided by the present invention is a system to carry out the method of the invention and a cassette suitable for carrying out the method of the invention on an automated radiosynthesis apparatus.

Embodiments of the present disclosure provide for -AApeptides, -AApeptide building blocks, methods of making -AApeptides and libraries of -AApeptides, methods of screening the -AApeptide libraries for desired peptidomimetic activity, and the like. The present disclosure also provides for -AApeptides that are inhibitors of A peptide aggregation, methods of inhibiting and disassembling A peptide aggregation, methods of inhibiting the toxicity of A aggregates towards N2a neuroblasotma cells, as well as methods and compounds for treating Alzheimer's disease.